A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer.

about

A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q52649579

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A retrospective study of shrin ...... II non-small cell lung cancer.

@en

A retrospective study of shrin ...... II non-small cell lung cancer.

@nl

type

Item

label

A retrospective study of shrin ...... II non-small cell lung cancer.

@en

A retrospective study of shrin ...... II non-small cell lung cancer.

@nl

prefLabel

A retrospective study of shrin ...... II non-small cell lung cancer.

@en

A retrospective study of shrin ...... II non-small cell lung cancer.

@nl

P1476

A retrospective study of shrin ...... II non-small cell lung cancer.

@en

P2093

Chenxue Jiang

http://www.w3.org/2001/XMLSchema#string

Guodong Shi

http://www.w3.org/2001/XMLSchema#string

He Wu

http://www.w3.org/2001/XMLSchema#string

Shuiyun Han

http://www.w3.org/2001/XMLSchema#string

Wucheng Chen

http://www.w3.org/2001/XMLSchema#string

Xiaojiang Sun

http://www.w3.org/2001/XMLSchema#string

Xiaozhen Ying

http://www.w3.org/2001/XMLSchema#string

Yaoyao Zhu

http://www.w3.org/2001/XMLSchema#string

Yaping Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto

Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer.

Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience

Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.

Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis.

Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.

Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost.

Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy.

Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?

P304

12443-12451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23849

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29552324

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

chemoradiotherapy

P932

5844760

http://www.w3.org/2001/XMLSchema#string